AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Anavex Life Sciences
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SLQWW6
1.33▼ 0.03 (-2.21%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.36
Day's Range
1.29 – 1.35
52-Week Range
1.14 – 9.40
Volume
598.7K
Avg Volume
1.2M
Share Statistics
Shares Outstanding
Employees
34
Exchange
XNAS
Listed
2006-08-02
Share count as of August 28, 2026

Anavex Life Sciences (AVXL) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Anavex Life Sciences (AVXL)
What is Anavex Life Sciences's Market Cap?
Anavex Life Sciences's Market Cap is $123.3M, based on as-reported figures from SEC (XBRL) filings.
What is Anavex Life Sciences's Enterprise Value?
Anavex Life Sciences's Enterprise Value is $5.0M, based on as-reported figures from SEC (XBRL) filings.
What is Anavex Life Sciences's Net Income (TTM)?
Anavex Life Sciences's Net Income (TTM) is -$13.0M, based on as-reported figures from SEC (XBRL) filings.
What is Anavex Life Sciences's Diluted EPS (TTM)?
Anavex Life Sciences's Diluted EPS (TTM) is -0.14, based on as-reported figures from SEC (XBRL) filings.
What is Anavex Life Sciences's Net Debt?
Anavex Life Sciences's Net Debt is -$118.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AVXLAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Selling, General and Administrative Expense——
Research and Development Expense——
Total operating expenses
Operating loss
Other income (expense)
Grant income———
Research and development incentive income
Net Interest Income
Other financing expense————
Foreign Currency Gain/Loss
Total other income, net
Net Income (Loss)
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—